Precision BioSciences, Inc. (NASDAQ:DTIL – Get Free Report) Director Geno J. Germano bought 3,605 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average cost of $4.49 per share, with a total value of $16,186.45. Following the purchase, the director now directly owns 7,807 shares of the company’s stock, valued at $35,053.43. This trade represents a 85.79 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Precision BioSciences Stock Performance
Shares of DTIL stock opened at $4.75 on Friday. The firm has a 50 day moving average of $6.44 and a 200-day moving average of $8.44. The company has a market cap of $36.44 million, a price-to-earnings ratio of 79.18 and a beta of 1.41. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34. Precision BioSciences, Inc. has a 52 week low of $3.61 and a 52 week high of $19.43.
Institutional Investors Weigh In On Precision BioSciences
An institutional investor recently raised its position in Precision BioSciences stock. Janus Henderson Group PLC increased its position in Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) by 10.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 702,069 shares of the company’s stock after buying an additional 68,943 shares during the period. Janus Henderson Group PLC owned 9.15% of Precision BioSciences worth $6,322,000 at the end of the most recent reporting period. 37.99% of the stock is owned by institutional investors and hedge funds.
About Precision BioSciences
Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
See Also
- Five stocks we like better than Precision BioSciences
- Market Cap Calculator: How to Calculate Market Cap
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
- Using the MarketBeat Dividend Yield Calculator
- Nebius Group: The Rising Star in AI Infrastructure
- What is a Stock Market Index and How Do You Use Them?
- MarketBeat Week in Review – 12/30 – 1/03
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.